首页> 外文期刊>JAMA ophthalmology >Experimental design issue for assessment of carotenoids lutein and zeaxanthin in age-related eye disease study 2 formulation for age-related macular degeneration
【24h】

Experimental design issue for assessment of carotenoids lutein and zeaxanthin in age-related eye disease study 2 formulation for age-related macular degeneration

机译:在年龄相关性眼病研究中评估类胡萝卜素叶黄素和玉米黄质的实验设计问题研究2年龄相关性黄斑变性的配方

获取原文
获取原文并翻译 | 示例
           

摘要

A recent assessment of the Age-Related Eye Disease Study 2 (AREDS2) trial of micronutrients for treatment of age-related macular degeneration (AMD) was very interesting, detailed, and insightful. One recommendation from the trial was to replace beta carotene in the supplement by the carotenoids lutein and zeaxanthin to minimize risk of lung cancer in smokers and ex-smokers. As observed by Musch, this was noteworthy for a clinical trial as it prompted recommendation for reformulation of the original AREDS supplement. A subsequent analysis of subgroups found improved confidence in recommending the replacement and revealed moderate improvements in risk reduction of AMD. One important issue deserves further comment and elaboration.
机译:最近一项有关微营养素治疗与年龄有关的黄斑变性(AMD)的年龄相关性眼病研究2(AREDS2)试验的最新评估非常有趣,详尽且有见地。该试验的一项建议是用类胡萝卜素叶黄素和玉米黄质代替补充物中的β-胡萝卜素,以最大程度地减少吸烟者和前吸烟者患肺癌的风险。正如Musch所观察到的那样,这对于临床试验是值得注意的,因为它促使人们建议重新配制原始AREDS补充剂。随后对亚组的分析发现,在推荐替代药物方面的信心得到了增强,并显示出AMD风险降低的适度改善。一个重要问题值得进一步评论和阐述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号